Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Buy
53
MDT Quote, Financials, Valuation and Earnings
Last price:
$90.11
Seasonality move
:
5.43%
Day range:
$89.70 - $90.84
52-week range:
$75.96 - $96.25
Dividend yield:
3.1%
P/E ratio:
27.40x
P/S ratio:
3.52x
P/B ratio:
2.34x
Volume:
5.4M
Avg. volume:
8.1M
1-year change:
8.49%
Market cap:
$115.6B
Revenue:
$32.4B
EPS (TTM):
$3.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$8.3B | $1.36 | 2.57% | 221.67% | $97.05 |
|
ABT
Abbott Laboratories
|
$11B | $1.34 | 4.19% | 52.11% | $136.97 |
|
BSX
Boston Scientific
|
$4.4B | $0.66 | 18.49% | 103.33% | $115.62 |
|
PODD
Insulet
|
$582M | $1.02 | 23.07% | 6.17% | $314.06 |
|
SYK
Stryker
|
$6.4B | $3.87 | 8.28% | 33.5% | $424.43 |
|
TMDX
TransMedics Group
|
$109.5M | $0.15 | 27.41% | -31.06% | $102.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$90.13 | $97.05 | $115.6B | 27.40x | $0.70 | 3.1% | 3.52x |
|
ABT
Abbott Laboratories
|
$127.21 | $136.97 | $220.6B | 16.63x | $0.59 | 1.76% | 5.30x |
|
BSX
Boston Scientific
|
$102.67 | $115.62 | $151.5B | 82.14x | $0.00 | 0% | 9.11x |
|
PODD
Insulet
|
$274.04 | $314.06 | $19.2B | 47.33x | $0.00 | 0% | 9.77x |
|
SYK
Stryker
|
$374.27 | $424.43 | $142.8B | 48.23x | $0.84 | 0.87% | 6.39x |
|
TMDX
TransMedics Group
|
$71.47 | $102.86 | $2.4B | 70.76x | $0.00 | 0% | 5.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDT
Medtronic PLC
|
34.97% | 0.928 | 22.74% | 1.19x |
|
ABT
Abbott Laboratories
|
22.86% | 0.603 | 7.72% | 1.23x |
|
BSX
Boston Scientific
|
32.79% | 0.683 | 8.05% | 0.46x |
|
PODD
Insulet
|
53.47% | 1.510 | 7.6% | 2.50x |
|
SYK
Stryker
|
39.72% | 1.452 | 10.13% | 1.11x |
|
TMDX
TransMedics Group
|
69.02% | 2.445 | 24.3% | 7.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$5.5B | $1.7B | 5.58% | 8.56% | 20.73% | $2.1B |
|
ABT
Abbott Laboratories
|
$6B | $1.9B | 24.06% | 32.63% | 19.74% | $2.1B |
|
BSX
Boston Scientific
|
$3.1B | $790M | 5.97% | 8.96% | 14.58% | $1.2B |
|
PODD
Insulet
|
$430.9M | $109.3M | 17.64% | 43.11% | 20.08% | $91.7M |
|
SYK
Stryker
|
$4.2B | $1.6B | 9.04% | 15.22% | 24.21% | $1.7B |
|
TMDX
TransMedics Group
|
$72M | $8.6M | 5.12% | 19.17% | 8.68% | $6.1M |
Medtronic PLC vs. Competitors
-
Which has Higher Returns MDT or ABT?
Abbott Laboratories has a net margin of 15.61% compared to Medtronic PLC's net margin of 84.1%. Medtronic PLC's return on equity of 8.56% beat Abbott Laboratories's return on equity of 32.63%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B ABTAbbott Laboratories54.97% $5.27 $62B -
What do Analysts Say About MDT or ABT?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 7.68%. On the other hand Abbott Laboratories has an analysts' consensus of $136.97 which suggests that it could grow by 7.67%. Given that Medtronic PLC has higher upside potential than Abbott Laboratories, analysts believe Medtronic PLC is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 ABTAbbott Laboratories13 7 0 -
Is MDT or ABT More Risky?
Medtronic PLC has a beta of 0.805, which suggesting that the stock is 19.493% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.
-
Which is a Better Dividend Stock MDT or ABT?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.1%. Abbott Laboratories offers a yield of 1.76% to investors and pays a quarterly dividend of $0.59 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or ABT?
Medtronic PLC quarterly revenues are $8.3B, which are smaller than Abbott Laboratories quarterly revenues of $11B. Medtronic PLC's net income of $1.3B is lower than Abbott Laboratories's net income of $9.2B. Notably, Medtronic PLC's price-to-earnings ratio is 27.40x while Abbott Laboratories's PE ratio is 16.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.52x versus 5.30x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.52x 27.40x $8.3B $1.3B ABTAbbott Laboratories5.30x 16.63x $11B $9.2B
-
Which has Higher Returns MDT or BSX?
Boston Scientific has a net margin of 15.61% compared to Medtronic PLC's net margin of 12.41%. Medtronic PLC's return on equity of 8.56% beat Boston Scientific's return on equity of 8.96%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B BSXBoston Scientific67.86% $0.38 $32.6B -
What do Analysts Say About MDT or BSX?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 7.68%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 12.61%. Given that Boston Scientific has higher upside potential than Medtronic PLC, analysts believe Boston Scientific is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 BSXBoston Scientific23 4 0 -
Is MDT or BSX More Risky?
Medtronic PLC has a beta of 0.805, which suggesting that the stock is 19.493% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.
-
Which is a Better Dividend Stock MDT or BSX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.1%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or BSX?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Boston Scientific quarterly revenues of $4.6B. Medtronic PLC's net income of $1.3B is higher than Boston Scientific's net income of $566M. Notably, Medtronic PLC's price-to-earnings ratio is 27.40x while Boston Scientific's PE ratio is 82.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.52x versus 9.11x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.52x 27.40x $8.3B $1.3B BSXBoston Scientific9.11x 82.14x $4.6B $566M
-
Which has Higher Returns MDT or PODD?
Insulet has a net margin of 15.61% compared to Medtronic PLC's net margin of 16.85%. Medtronic PLC's return on equity of 8.56% beat Insulet's return on equity of 43.11%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B PODDInsulet72.12% $1.39 $2.6B -
What do Analysts Say About MDT or PODD?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 7.68%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 14.6%. Given that Insulet has higher upside potential than Medtronic PLC, analysts believe Insulet is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 PODDInsulet14 4 0 -
Is MDT or PODD More Risky?
Medtronic PLC has a beta of 0.805, which suggesting that the stock is 19.493% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.
-
Which is a Better Dividend Stock MDT or PODD?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.1%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or PODD?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Insulet quarterly revenues of $597.5M. Medtronic PLC's net income of $1.3B is higher than Insulet's net income of $100.7M. Notably, Medtronic PLC's price-to-earnings ratio is 27.40x while Insulet's PE ratio is 47.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.52x versus 9.77x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.52x 27.40x $8.3B $1.3B PODDInsulet9.77x 47.33x $597.5M $100.7M
-
Which has Higher Returns MDT or SYK?
Stryker has a net margin of 15.61% compared to Medtronic PLC's net margin of 8.48%. Medtronic PLC's return on equity of 8.56% beat Stryker's return on equity of 15.22%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B SYKStryker64.85% $1.41 $34.2B -
What do Analysts Say About MDT or SYK?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 7.68%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 13.4%. Given that Stryker has higher upside potential than Medtronic PLC, analysts believe Stryker is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 SYKStryker13 9 0 -
Is MDT or SYK More Risky?
Medtronic PLC has a beta of 0.805, which suggesting that the stock is 19.493% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.
-
Which is a Better Dividend Stock MDT or SYK?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.1%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or SYK?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Stryker quarterly revenues of $6.4B. Medtronic PLC's net income of $1.3B is higher than Stryker's net income of $546M. Notably, Medtronic PLC's price-to-earnings ratio is 27.40x while Stryker's PE ratio is 48.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.52x versus 6.39x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.52x 27.40x $8.3B $1.3B SYKStryker6.39x 48.23x $6.4B $546M
-
Which has Higher Returns MDT or TMDX?
TransMedics Group has a net margin of 15.61% compared to Medtronic PLC's net margin of 5.64%. Medtronic PLC's return on equity of 8.56% beat TransMedics Group's return on equity of 19.17%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B TMDXTransMedics Group59.21% $0.19 $737.9M -
What do Analysts Say About MDT or TMDX?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 7.68%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 43.92%. Given that TransMedics Group has higher upside potential than Medtronic PLC, analysts believe TransMedics Group is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 TMDXTransMedics Group5 3 0 -
Is MDT or TMDX More Risky?
Medtronic PLC has a beta of 0.805, which suggesting that the stock is 19.493% less volatile than S&P 500. In comparison TransMedics Group has a beta of 2.121, suggesting its more volatile than the S&P 500 by 112.09%.
-
Which is a Better Dividend Stock MDT or TMDX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.1%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or TMDX?
Medtronic PLC quarterly revenues are $8.3B, which are larger than TransMedics Group quarterly revenues of $121.6M. Medtronic PLC's net income of $1.3B is higher than TransMedics Group's net income of $6.9M. Notably, Medtronic PLC's price-to-earnings ratio is 27.40x while TransMedics Group's PE ratio is 70.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.52x versus 5.70x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.52x 27.40x $8.3B $1.3B TMDXTransMedics Group5.70x 70.76x $121.6M $6.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is down 9.27% over the past day.
Buy
58
TNXP alert for Mar 25
Tonix Pharmaceuticals Holding [TNXP] is down 1.51% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 0.66% over the past day.
